Roche wins FDA approval for Wilserdly in ESR1-mutated advanced breast cancer
- Wilserdly (giredestrant) plus everolimus is approved for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after endocrine therapy.
- In phase III evERA, the combination reduced the risk of disease progression or death by 62% versus standard endocrine therapy plus everolimus (HR 0.38).
- ESR1 mutations, a cause of endocrine therapy resistance, affect up to 40% of patients with HR-positive metastatic breast cancer.
- The FDA is reviewing Wilserdly for adjuvant use, with a decision expected by 30 November 2026.
FDA approval
The FDA approved Roche’s Wilserdly (giredestrant) with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The indication covers disease recurring during or after endocrine-based adjuvant therapy, or progressing on at least one endocrine-based regimen in the metastatic setting. ESR1 mutations are reported in up to 40% of patients with HR-positive metastatic breast cancer and are associated with resistance to hormone therapy.
Phase III evidence
Approval was supported by the evERA study in patients whose disease had progressed after CDK4/6 inhibitor therapy. The combination significantly prolonged progression-free survival, reducing the risk of progression or death by 62% versus standard endocrine therapy plus everolimus (hazard ratio 0.38; 95% confidence interval 0.27–0.54; p<0.0001). Both medicines are taken orally.
Adjuvant application
The FDA is also reviewing Wilserdly as adjuvant treatment for adults with ER-positive, HER2-negative stage I–III breast cancer at intermediate to high risk of recurrence. The application, based on the phase III lidERA study, received Priority Review. The FDA’s decision date is 30 November 2026.
Source: Roche